Mesoblast Ltd.


ASX-listed, Melbourne headquartered health care player Mesoblast Limited (ASX:MSB) is a frontrunner in developing innovative cellular medicines across the globe. MSB has a strong emerging drug pipeline with its three programs currently under phase III clinical studies. The lead drug candidates of Mesoblast remestemcel-L, revascor, MPC-300-IV and MPC-06-ID are under clinical development. The Company has a robust and broad worldwide intellectual property portfolio with protection extending through to at least 2040 in all main markets.

Contact Information

company address Level 38, 55 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000

company phone(03) 9639 6036

company website

Similar Companies

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK